Abstract 425P
Background
Palonosetron (PALO) is a second-generation 5-hydroxytryptamine 3 receptor antagonist (5HT3RA) that has shown better efficacy than first-generation 5HT3RA (granisetron; GRA) in preventing chemotherapy-induced nausea and vomiting (CINV). PALO is usually administrated repeatedly when the patients have no nausea even though it is expensive as compared with GRA. However, we could reduce medical costs for chemotherapy if 5HT3RA conversion from PALO to GRA in the patient without having CINV is safe and tolerable.
Methods
We prospectively investigated patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC) in combination with PALO for digestive organ cancers in accordance with guideline of Japan Society of Clinical Oncology. Patients assessed as complete response (CR) during the acute phase (0-24 h postchemotherapy) and the delayed phase (24-120 h postchemotherapy) in consecutive treatments were converted their antiemetic agents from PALO to GRA. We evaluated the incidence of CINV and the cost-effectiveness.
Results
Thirty five cases (madian age 73 years, female 51.4%, 18; pancreatic cancer, 8; colorectal cancer, 3; esophageal cancer, 3; gastric cancer, 3; biliary tract cancer) were enrolled at our institution between January 2018 and June 2019. Ten cases were administrated HEC (HEC group) and 25 cases were administrated MEC (MEC group). One case of HEC group and 2 cases of MEC group changed their chemotherapy regimens due to adverse events and progression of disease. Four cases of HEC group (40.0%) and 14 cases of MEC group (56.0%) were assessed as CR in consecutive treatments, thereafter their antiemetic agents were converted from PALO to GRA in the subsequent treatments. All of them continued their chemotherapy without the incidence of nausea and vomiting. Among the cases assessed as CR, we could save 111,935 Japanese yen (1,034.6 USD, range, 13,868-194,152 JPY) per case by conversion of 5HT3RA.
Conclusions
Our data indicated that the conversion of 5HT3RA is safe and also provide economic benefit in patients receiving HEC or MEC. When patients receiving HEC or MEC with PALO were assessed as CR, we should consider conversion of 5HT3RA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asahikawa medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract